Combination acne medications provide enhanced treatment opportunities. A commonly used acne therapy may combine a topical antibiotic with benzoyl peroxide (BPO) to prevent antibiotic resistance while optimizing control of microcomedone formation with a retinoid. Unfortunately, this combination of highly efficacious medications may cause irritation because of the inherent skin irritancy of BPO and retinoids. The present study was undertaken to determine if vehicle optimization of a clindamycin-BPO formulation could increase the tolerability of an added retinoid. Forty-six women with mild to moderate facial acne were enrolled in a 3-center, institutional review board-approved, 2-week, split-face study to compare an optimized vehicle (glycerin and dimethicone) clindamycin-BPO formulation with a traditional clindamycin-BPO formulation, with tretinoin cream 0.025% applied to the entire face. The use of the optimized vehicle clindamycin-BPO formulation in combination with tretinoin cream 0.025% resulted in significantly less erythema and dryness on evaluation days 4, 7, and 14 (P < .05), as assessed by the blinded dermatologist investigators. The incorporation of new vehicles into topical dermatologic medications allows medication combinations with enhanced tolerability.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Updates on Topical Dyad and Triple Combination Therapies Approved for Acne Vulgaris.
Cureus
May 2024
Dermatology, Lewis Katz School of Medicine at Temple University, Philadelphia, USA.
Article Synopsis
- Acne vulgaris is a complex skin condition with both inflammatory and noninflammatory lesions, and using combination topical therapies can effectively target multiple causes in a single treatment.
- Clindamycin phosphate/benzoyl peroxide/adapalene is the first FDA-approved triple therapy that shows significant effectiveness against acne while having a low side effect profile.
- A literature review from 2018 to 2023 examined various combination treatments and found that these multi-drug formulations improve patient adherence and offer a promising solution for managing acne vulgaris.
A 3-step acne system has been developed to enhance the bioavailability and follicular penetration of benzoyl peroxide (BPO). Participants with mild to moderate facial acne vulgaris were randomly assigned to 10 weeks' facial treatment with the 3-step acne system (proprietary salicylic acid cleanser 2% twice daily, proprietary salicylic acid toner 2% once daily, and solubilized BPO gel 5% twice daily) or with control cleanser twice daily plus clindamycin 1%-BPO 5% gel (jar formulation) twice daily. Among 139 participants enrolled, the 3-step acne system was at least as effective as clindamycin-BPO in reducing noninflammatory lesion counts in the early weeks of treatment in the absence of an antibiotic (mean reductions were 27% vs 13%, 39% vs 25%, 40% vs 33%, and 42% vs 42% at weeks 2, 4, 6, and 10, respectively) (all not significant).
View Article and Find Full Text PDFThe development and optimization of a fixed combination of clindamycin and benzoyl peroxide aqueous gel.
J Drugs Dermatol
July 2009
Dow Pharmaceutical Sciences, Inc., Petaluma, CA 94954-7121, USA.
Fixed combination products of clindamycin 1% (as 1.2% clindamycin phosphate) and benzoyl peroxide (BPO) 5% are commonly used in the treatment of acne vulgaris. Although any given topical acne product may be therapeutically effective, signs and symptoms of cutaneous tolerability may lead to missed applications by the patient, thus limiting adherence to therapy.
View Article and Find Full Text PDFThe effect of vehicle formulation on acne medication tolerability.
Cutis
October 2008
Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Combination acne medications provide enhanced treatment opportunities. A commonly used acne therapy may combine a topical antibiotic with benzoyl peroxide (BPO) to prevent antibiotic resistance while optimizing control of microcomedone formation with a retinoid. Unfortunately, this combination of highly efficacious medications may cause irritation because of the inherent skin irritancy of BPO and retinoids.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!